|
|
Volumn 23, Issue 24, 2005, Pages 5417-5419
|
|
Imaging and other biomarkers in early clinical studies: One step at a time or re-engineering drug development?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANGIOGENESIS INHIBITOR;
ANTIARRHYTHMIC AGENT;
ANTIMITOTIC AGENT;
ANTINEOPLASTIC AGENT;
AXITINIB;
BIOLOGICAL MARKER;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ESTRAMUSTINE;
ESTROGEN RECEPTOR;
TRASTUZUMAB;
VASCULAR TARGETING AGENT;
IMIDAZOLE DERIVATIVE;
INDAZOLE DERIVATIVE;
NEW DRUG;
TUMOR MARKER;
ALKYLATION;
BIOMEDICAL ENGINEERING;
BLOOD FLOWMETRY;
BLOOD VOLUME;
BREAST CANCER;
CANCER RISK;
CLINICAL STUDY;
DOSE RESPONSE;
DRUG INDICATION;
DRUG MANUFACTURE;
DRUG RESEARCH;
DRUG SCREENING;
EDITORIAL;
ELECTROCARDIOGRAPHY;
HEART ARRHYTHMIA;
HISTOPATHOLOGY;
HUMAN;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
TOXICITY;
TREATMENT RESPONSE;
CLINICAL TRIAL;
DIAGNOSTIC IMAGING;
DRUG DESIGN;
NEOPLASM;
NEOVASCULARIZATION (PATHOLOGY);
NOTE;
ORAL DRUG ADMINISTRATION;
ADMINISTRATION, ORAL;
ANGIOGENESIS INHIBITORS;
CLINICAL TRIALS;
DIAGNOSTIC IMAGING;
DRUG DESIGN;
DRUGS, INVESTIGATIONAL;
HUMANS;
IMIDAZOLES;
INDAZOLES;
NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 24944564335
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.05.907 Document Type: Editorial |
|
Times cited : (25)
|
|
References (8)
|
